740-P: Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting

Introduction 63.9% of patients were persistent throughout their variable follow up period. Basic demographic and clinical characteristics were similar between persistent and non-persistent patients. At 6 months, 80.2% of patients were persistent; the percentage was 63.2% and 54.3% at 12 and 18 months, respectively. PDC was 0.72, 0.68, and 0.66 among patients with at least 6, 12, or 18 months of follow up, respectively. Conclusions: Patients had at least two-thirds of PDC and 63.9% of them were persistent throughout their follow up. Identifying factors influencing persistence and adherence is imperative to guide interventions aimed at enhancing these aspects, thereby maximizing the cardiovascular benefits derived from GLP-1 RAs. Disclosure T. Dunn: Employee; Novo Nordisk. Y. Zhu: Employee; UnitedHealth Group. Stock/Shareholder; UnitedHealth Group. Other Relationship; UnitedHealth Group, Novo Nordisk. N. Gronroos: Other Relationship; UnitedHealth Group, Novo Nordisk. Stock/Shareholder; UnitedHealth Group. Employee; UnitedHealth Group. L. Xie: None. J. Noone: Employee; Novo Nordisk. A. Sargent: Other Relationship; Novo Nordisk. Employee; UnitedHealth Group. Other Relationship; UnitedHealth Group. L. Yedigarova: Employee; Novo Nordisk. Stock/Shareholder; AbbVie Inc. L.K. Billings: Advisory Panel; Novo Nordisk, Pfizer Inc. Funding Novo Nordisk, Inc.